ALNYLAM PHARMACEUTICALS, INC. SG&A Expense 2016-2025 | ALNY
What is sg&a expense?
Selling, general, and administrative expenses include all non-production costs such as marketing, corporate overhead, and management salaries.
What is ALNYLAM PHARMACEUTICALS, INC.'s current sg&a expense?
ALNYLAM PHARMACEUTICALS, INC. (ALNY) annual sg&a expense for 2025 was $1.21B, a 24.11% increase from 2024. ALNYLAM PHARMACEUTICALS, INC. sg&a expense for the quarter ending December 31, 2025 was $325.4M.
What was ALNYLAM PHARMACEUTICALS, INC.'s sg&a expense in 2024?
ALNYLAM PHARMACEUTICALS, INC. annual sg&a expense for 2024 was $975.5M, a 22.61% increase from 2023.
What was ALNYLAM PHARMACEUTICALS, INC.'s sg&a expense in 2023?
ALNYLAM PHARMACEUTICALS, INC. annual sg&a expense for 2023 was $795.6M, a 3.24% increase from 2022.
What is ALNYLAM PHARMACEUTICALS, INC.'s 5-year sg&a expense CAGR?
ALNYLAM PHARMACEUTICALS, INC. sg&a expense grew at a compound annual growth rate (CAGR) of 15.52% from FY2020 to FY2025, going from $588.4M to $1.21B over 5 years.
Year-over-year comparison from 10-K annual reports